Antitrust Antitrust

Teva, Cephalon get extra set of EU antitrust charges in pay-for-delay probe (update*)

By Michael Acton
  • 08 Jun 2020 06:18
  • 08 Jun 2020 08:09
Teva and Cephalon have received supplementary charges as part of an ongoing EU antitrust probe into the two pharmaceutical companies over suspected “pay-for-delay” agreements, the European Commission said.

The fresh set of charges follows an initial statement of objections sent to the companies in July 2017. 

The EU regulator said today (see here) that

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News